Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant

This trial tests a new drug called AT 1501, which works differently from standard anti-rejection medications used after kidney transplants. It targets a specific immune pathway to prevent the body from attacking the new kidney, and researchers are studying whether it is safe and effective when added to standard care. **You may be eligible if...** - You are 18 or older - You are receiving your first kidney transplant from a living or deceased donor - You agree to use contraception during and for 90 days after taking the study drug **You may NOT be eligible if...** - You have previously had a bone marrow transplant or any other organ transplant - You are receiving a multi-organ or dual kidney transplant - You have already been treated with immunosuppressive medications (other than low-dose prednisone) - The donated kidney is expected to be stored in ice for more than 30 hours - The donor kidney comes from an extended criteria donor (older age with specific health conditions) or donation after cardiac death Talk to your doctor to see if this trial is right for you.